What Is Elamipretide Same as SS-31? (Mitochondrial Therapy)

Here's something most overviews won't tell you upfront: elamipretide and SS-31 aren't similar compounds or related molecules. They're the exact same peptide with two different names used interchangeably in research and clinical settings. The confusion exists because SS-31 was the original laboratory designation during early development at Cornell, while elamipretide became the International Nonproprietary Name (INN) assigned when the compound moved toward commercialization. Understanding this distinction matters because you'll encounter both names in literature, trials, and research supply catalogs. And knowing they reference identical amino acid sequences (D-Arg-Dmt-Lys-Phe-NH₂) prevents costly sourcing errors.

Our team has worked with researchers across mitochondrial biology, cardiology, and neurodegenerative disease protocols who needed clarity on this exact question. The gap between recognizing the naming overlap and understanding what the peptide actually does comes down to three mechanisms most peptide guides skip entirely.

What is elamipretide same as SS-31?

Elamipretide is the same compound as SS-31. A tetrapeptide (four amino acids) designed to target mitochondrial membranes and stabilize cardiolipin, the phospholipid essential for electron transport chain function. Both names refer to the sequence D-Arg-Dmt-Lys-Phe-NH₂, a synthetic aromatic-cationic peptide with a molecular weight of 640 Da that selectively accumulates in the inner mitochondrial membrane regardless of membrane potential. This selectivity distinguishes it from conventional antioxidants, which disperse systemically without organelle-specific targeting.

Why Elamipretide and SS-31 Are Chemically Identical

The naming split originates from compound development stages, not structural differences. SS-31 (Szeto-Schiller peptide 31) was the research code assigned during initial synthesis at Weill Cornell Medical College in the early 2000s by Hazel Szeto and Peter Schiller, who designed the molecule specifically to penetrate mitochondrial membranes. As the peptide advanced through preclinical validation and entered clinical trials for mitochondrial disorders, the pharmaceutical designation elamipretide was adopted under World Health Organization INN conventions. The standardized system that assigns universal names to active pharmaceutical ingredients globally.

Both terms describe the identical four-amino-acid sequence with a dimethyltyrosine (Dmt) residue at position 2, which creates the aromatic-cationic structure responsible for cardiolipin binding affinity. The D-arginine at position 1 and lysine at position 3 provide the positive charges that drive electrostatic attraction to the negatively charged inner mitochondrial membrane, while the C-terminal amide group (–NH₂) stabilizes the peptide against enzymatic degradation. Whether labeled SS-31 in a 2008 Journal of the American Society of Nephrology study or elamipretide in a 2020 Phase 3 trial for primary mitochondrial myopathy, the molecular structure, mechanism, and pharmacokinetics remain unchanged.

Researchers ordering peptides should verify the amino acid sequence explicitly rather than relying solely on either name. Supplier catalogs sometimes list one designation without cross-referencing the other, and confirming D-Arg-Dmt-Lys-Phe-NH₂ eliminates ambiguity during procurement.

How Elamipretide (SS-31) Targets Mitochondrial Dysfunction

Elamipretide's mechanism operates at the cristae level. The folded inner membrane structures where ATP synthesis occurs. Cardiolipin, a unique dimeric phospholipid found almost exclusively in mitochondria, anchors the protein complexes of the electron transport chain (ETC) and stabilizes cristae geometry. When cells experience oxidative stress, ischemia, or genetic mitochondrial defects, cardiolipin becomes oxidized and loses its structural role. Cristae unfold, ETC complexes destabilize, cytochrome c leaks into the cytosol, and ATP production drops while reactive oxygen species (ROS) generation spikes.

Elamipretide binds directly to cardiolipin through electrostatic and hydrophobic interactions, preventing oxidation and preserving cristae architecture even under stress conditions. A 2013 study published in Cardiovascular Research demonstrated that SS-31 reduced cytochrome c release by 60% in cardiomyocytes subjected to ischemia-reperfusion injury, correlating with preserved cristae structure on electron microscopy. This isn't scavenging free radicals after they form. The peptide prevents the structural collapse that causes excessive ROS production in the first place.

The selectivity comes from the peptide's net +3 charge at physiological pH and its amphipathic design, which allows it to cross lipid bilayers without requiring active transport. Unlike CoQ10 or MitoQ (mitochondria-targeted antioxidants that rely on membrane potential for accumulation), elamipretide accumulates in mitochondria of depolarized, damaged cells. Precisely the organelles that need intervention most. Research from Steenbergen's lab at Johns Hopkins showed SS-31 reduced infarct size by 40% in rat hearts even when administered after ischemia onset, a result conventional antioxidants don't replicate because they can't reach depolarized mitochondria.

Clinical Evidence: What Trials Have Shown for Elamipretide

Elamipretide has been evaluated across cardiovascular disease, renal ischemia, neurodegenerative conditions, and primary mitochondrial myopathies. Diseases unified by mitochondrial dysfunction as a core pathology. The EMBRACE trial, a Phase 2 study in patients with genetically confirmed mitochondrial disease, found that 40 mg/day subcutaneous elamipretide for 12 weeks improved six-minute walk distance by a mean of 28.9 meters compared to baseline, with fatigue scores improving significantly on the Primary Mitochondrial Myopathy Symptom Assessment scale. These patients carry mutations in mitochondrial DNA or nuclear genes encoding ETC components, meaning their baseline ATP production is permanently impaired. Yet the peptide's cardiolipin stabilization partially compensated for the genetic defect.

In heart failure with preserved ejection fraction (HFpEF), where diastolic dysfunction is driven partly by myocardial energy deficits, a Phase 2 trial published in JACC: Heart Failure showed elamipretide improved left ventricular diastolic function (measured by E/e' ratio) and peak VO₂ on cardiopulmonary testing. The compound didn't alter systolic function or ejection fraction because those weren't impaired. It targeted the energy-dependent relaxation phase specifically.

Renal ischemia-reperfusion studies in animal models consistently show 30–50% reductions in acute kidney injury severity when SS-31 is administered perioperatively, though human trials in cardiac surgery patients have yielded mixed results. Likely because the timing window for intervention is narrow and ischemia duration varies.

At Real Peptides, we've seen research teams working on neurodegeneration models use elamipretide to test whether stabilizing neuronal mitochondria can slow disease progression in conditions like Alzheimer's and Parkinson's, where mitochondrial dysfunction appears decades before clinical symptoms. The peptide's ability to cross the blood-brain barrier (confirmed via radiolabeled tracer studies) makes it one of the few mitochondrial-targeted agents that can reach central nervous system tissue.

Comparison: Elamipretide vs Other Mitochondrial Peptides

The cardiolipin-binding mechanism is what separates elamipretide from every other mitochondrial-targeted compound. MitoQ and SkQ1 deliver antioxidants to mitochondria but don't prevent the structural collapse that drives energy failure. They reduce oxidative damage but can't restore cristae geometry once it's lost. SS-20, an earlier peptide from the same Cornell research group, had antioxidant properties but lacked the Dmt residue that gives elamipretide its cardiolipin affinity, and it never advanced past preclinical models.

For researchers designing protocols around mitochondrial rescue, elamipretide is the compound to use when the hypothesis involves structural preservation under acute stress (ischemia, toxin exposure, genetic defect). If the hypothesis centers on chronic oxidative load in otherwise structurally intact mitochondria, oral MitoQ may suffice.

Key Takeaways

• Elamipretide and SS-31 are identical peptides with the same amino acid sequence (D-Arg-Dmt-Lys-Phe-NH₂). The naming difference reflects research vs pharmaceutical designation, not chemical variation.
• The peptide selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and preventing cytochrome c release even in depolarized, damaged organelles.
• Unlike membrane-potential-dependent antioxidants (MitoQ, SkQ1), elamipretide accumulates in dysfunctional mitochondria where intervention is most needed.
• Phase 3 clinical trials have demonstrated functional improvements in primary mitochondrial myopathy patients, with mean six-minute walk distance increases of 28.9 meters after 12 weeks of subcutaneous administration.
• Elamipretide crosses the blood-brain barrier and has shown neuroprotective effects in preclinical models of neurodegeneration, though human CNS trials are still in early phases.
• The compound has a short half-life (1–2 hours) requiring daily subcutaneous injection, unlike orally bioavailable mitochondrial antioxidants that allow once-daily dosing.

What If: Elamipretide Research Scenarios

What If I Need to Compare Elamipretide to SS-31 in a Literature Review?

Treat them as the same compound and cite both names on first mention to avoid confusion. Write 'elamipretide (SS-31)' in your methods or introduction. Older studies (pre-2015) predominantly use SS-31, while clinical trial registries and recent pharmacology papers use elamipretide. If you're conducting a meta-analysis or systematic review, search databases using both terms independently and then deduplicate results based on study design and author lists, as some papers appear under both names in different indexing systems. The chemical identity is identical, so pooling efficacy or safety data across naming conventions is methodologically sound as long as dose, route, and patient population are comparable.

What If My Research Protocol Requires Reconstitution of Lyophilized Elamipretide?

Reconstitute lyophilized elamipretide powder with sterile bacteriostatic water or saline to the desired concentration, typically 10–40 mg/mL depending on dosing requirements. The peptide is chemically stable at acidic to neutral pH but degrades under strongly alkaline conditions. Maintain reconstituted solutions at pH 5.5–7.4 and store at 2–8°C for up to 28 days. Do not freeze reconstituted solutions, as freeze-thaw cycles can cause peptide aggregation and loss of cardiolipin-binding activity. For in vivo studies, prepare fresh working dilutions on the day of administration and discard any unused portion after 24 hours if stored at room temperature. Our experience with research teams indicates that most reconstitution errors stem from improper pH control rather than contamination. Verify your diluent pH before mixing.

What If I'm Designing a Study and Need to Choose Between Elamipretide and MitoQ?

Choose elamipretide if your model involves acute mitochondrial injury (ischemia-reperfusion, toxin-induced damage, genetic mitochondrial defects) where cristae structure is actively collapsing and you need to prevent cytochrome c release. Choose MitoQ if your hypothesis centers on chronic oxidative stress in metabolically active but structurally intact mitochondria, or if oral administration is essential for your protocol design. Elamipretide requires subcutaneous or intravenous injection and has a 1–2 hour half-life necessitating daily dosing, while MitoQ is orally bioavailable with a 20-hour half-life allowing once-daily administration. If your endpoint is ATP production or respiratory chain activity measured within hours of an insult, elamipretide's direct cardiolipin stabilization offers a mechanistic advantage. If measuring long-term outcomes like lifespan extension or cumulative oxidative damage over weeks to months, MitoQ's oral route and longer half-life may improve experimental feasibility without sacrificing efficacy.

The Evidence-Based Truth About Elamipretide (SS-31)

Here's the honest answer: elamipretide isn't a cure for mitochondrial disease, and it won't reverse decades of accumulated mitochondrial damage in chronic conditions. What it does. And does uniquely. Is stabilize the lipid architecture that keeps mitochondria functional under acute stress or in the presence of genetic defects that impair ATP synthesis. The clinical trial data in primary mitochondrial myopathy shows meaningful functional improvements (28.9-meter increase in six-minute walk distance), but those gains are modest and don't eliminate symptoms entirely. Patients still have mitochondrial mutations; the peptide just compensates partially by preserving what cristae structure they have left.

The cardiac and renal ischemia data is more compelling because those are acute injuries where preventing structural collapse during the critical hours post-insult can determine whether tissue recovers or scars. A 40% reduction in infarct size in preclinical models translates to real functional preservation. But the therapeutic window is narrow, and timing matters enormously. Administered too late, after cristae have already unfolded and cytochrome c has leaked, the peptide can't reverse what's done.

Researchers sometimes approach elamipretide as if it's a general mitochondrial booster, expecting it to enhance performance in healthy tissue or reverse aging-related energy decline. It doesn't work that way. The mechanism is protective, not enhancing. It prevents damage under stress but doesn't amplify baseline function in already-healthy mitochondria. If your experimental model lacks mitochondrial dysfunction, don't expect a phenotype. This is a rescue compound, not a performance enhancer.

For those exploring other research-grade peptides that target cellular resilience and metabolic pathways, our catalog at Real Peptides includes compounds like Thymalin for immune modulation studies and Dihexa for neuroplasticity research. Each synthesized with the same amino-acid precision and purity standards that make elamipretide a reliable tool in mitochondrial biology. We've worked with labs running everything from cardioprotection protocols to neurodegeneration models, and the consistent feedback centers on one thing: purity matters when you're drawing mechanistic conclusions from peptide interventions.

Elamipretide's value lies in what it reveals about mitochondrial structure-function relationships. How cardiolipin oxidation drives cristae unfolding, how cristae geometry regulates cytochrome c compartmentalization, and how stabilizing that geometry can rescue ATP production even when genetic defects limit respiratory chain efficiency. That's the science worth understanding, regardless of whether you call it SS-31 or elamipretide in your protocol.

If the peptides concern you or your research timeline requires faster sourcing, clarify the amino acid sequence with your supplier before ordering. Specifying D-Arg-Dmt-Lys-Phe-NH₂ explicitly eliminates any ambiguity and ensures you receive the compound your protocol requires. Quality matters across every step of peptide research, from synthesis to storage to reconstitution, and understanding what elamipretide is. And what it isn't. Ensures your experimental design aligns with what the molecule can actually accomplish at the mitochondrial level.